title: Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular-weight heparin enoxaparin.
abstract: The nephrotic syndrome (NS) carries one of the highest risks of thrombotic complications. Consequently, over the last 15 years, some nephrologists have treated patients risk (i.e. those with albuminemia < 20 g/l and membranous nephropathy) with anticoagulants: either subcutaneous heparin (Kakkar protocol) or antivitamin K. Low-molecular-weight heparin (LMWH) has a longer plasma half-life and better bioavailability than standard heparin and can thus be administered as a single daily injection. LMWH also carries a lower risk of hemorrhage. We prospectively studied the safety and efficacy of the LMWH Enoxaparin for preventive anticoagulation in NS. In a preliminary study, 10 adult nephrotic patients with biological markers of thrombosis risk (severe hypoalbuminemia and/or anomalies of the fibrinolytic pathway and/or deficiency in coagulation inhibitors) were given 40 mg (4,000 U) of Enoxaparin daily for at least 3 months; 3 patients were treated for 3 months, 1 for 6 months and 6 for 12 months. Patients were assessed for silent thrombosis, using renal vein Doppler ultrasonography, lower leg vein Doppler ultrasonography and lung ventilation-perfusion scintigraphy, before entry to the trial and subsequently at 3-month intervals. As LWMH caused no obvious side effects and no thrombosis was observed during the pilot study, we then placed 55 adult nephrotic patients free of thrombosis on the same treatment. Patients were seen according to the usual calendar required by their individual illnesses. At each examination, patients were assessed for clinical signs and symptoms of thrombosis and side effects; plasma D-dimer and urinary fibrin-fibrinogen degradation products were also measured at each visit.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Service de Néphrologie, Hôpital Henri-Mondor, Créteil, France.
authors.forename: G
authors.initials: G
authors.lastname: Rostoker
authors.forename: I
authors.initials: I
authors.lastname: Durand-Zaleski
authors.forename: M
authors.initials: M
authors.lastname: Petit-Phar
authors.forename: A
authors.initials: A
authors.lastname: Ben Maadi
authors.forename: N
authors.initials: N
authors.lastname: Jazaerli
authors.forename: C
authors.initials: C
authors.lastname: Radier
authors.forename: A
authors.initials: A
authors.lastname: Rahmouni
authors.forename: D
authors.initials: D
authors.lastname: Mathieu
authors.forename: N
authors.initials: N
authors.lastname: Vasile
authors.forename: J
authors.initials: J
authors.lastname: Rosso
mesh_terms: D000328:Adult; D001706:Biopsy; D015331:Cohort Studies; D017984:Enoxaparin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015994:Incidence; D007668:Kidney / Q000187:drug effects / Q000473:pathology / Q000502:physiology; D008297:Male; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000150:complications* / Q000453:epidemiology; D011446:Prospective Studies; D011507:Proteinuria / Q000188:drug therapy / Q000652:urine; D012082:Renal Veins; D012307:Risk Factors; D013927:Thrombosis / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*
chemical_list: D017984:Enoxaparin